Circassia to take up full US rights on Tudorza

11 December 2018

UK biotech firm Circassia Pharmaceuticals (LSE: CIR) today announced that it is exercising its option to acquire the full US commercial rights to Tudorza (aclidinium) from AstraZeneca (LSE: AZN).

Circassia currently promotes the chronic obstructive pulmonary disease (COPD) treatment in the USA under a profit share arrangement established by the two companies in April 2017. Circassia anticipates completing the option exercise on December 31, 2018.

Following the news, Circassia’s shares closed down 5.61% at 62.30 pence, while AstraZeneca’s shares were up 1.90% at £61.21.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK